Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis

ClinicalTrials.gov ID: NCT00570752

Public ClinicalTrials.gov record NCT00570752. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to determine whether a p38 kinase inhibitor reduces inflammation in atherosclerotic plaque

Study identification

NCT ID
NCT00570752
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
72 participants

Conditions and interventions

Interventions

Other · Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2008
Primary completion
Oct 31, 2010
Completion
Nov 30, 2010
Last update posted
Dec 6, 2015

2008 – 2010

United States locations

U.S. sites
17
U.S. states
11
U.S. cities
16
Facility City State ZIP Site status
Southeast Clinical Research, Llc Chiefland Florida 32626
Jacksonville Center For Clinical Research - Univ Campus Jacksonville Florida 32216
Florida Cardiovascular Institute Tampa Florida 33609
Phillip D. Toth, Md Indianapolis Indiana 46260
L-Marc Research Center Louisville Kentucky 40213
Commonwealth Biomedical Research, Llc Madisonville Kentucky 42431
Mgh Cardiac Mr Pet Ct Program Boston Massachusetts 02114
Troy Internal Medince Pc/Research Troy Michigan 48098
Radiant Research, Inc. Edina Minnesota 55435
Mount Sinai School Of Medicine Imaging Science Laboratories New York New York 10029
The Lipid Center Statesville North Carolina 28677
Metabolic And Atherosclerosis Research Center Cincinnati Ohio 45212
Sterling Research Group Cincinnati Ohio 45219
Hospital Of The University Of Pennsylvania Philadelphia Pennsylvania 19104
Radiant Research, Inc. Dallas Texas 75231
Baylor College Of Medicine Houston Texas 77030
Mcallen Heart Clinic McAllen Texas 78503

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00570752, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 6, 2015 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00570752 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →